NANTES, FRANCE--(Marketwire - June 8, 2010) - VIVALIS (NYSE Euronext: VLS) announced today the signature with Sanofi Pasteur, the vaccines division of sanofi-aventis Group (Euronext: SAN and NYSE: SNY ...

Vivalis strengthens its management team with the appointment of Philippe Rousseau, as Chief Financial Officer VIVALIS (PARIS: VLS), a biopharmaceutical company that provides the pharmaceutical ...

PARIS, Nov 24 (Reuters) - French biotech firm Vivalis and British partner GlaxoSmithKline have won U.S. clearance to begin testing on humans for the first time flu vaccines which were produced using ...

Vivalis and Intercell have agreed to the terms of a merger to create a new European biotechnology company called Valneva that will specialize in vaccines and antibodies. Vivalis and Intercell have ...

Firm is developing VLP-based vaccines. Vivalis has granted Novavax the right to use its EB66® cell line for the production of VLP-based vaccines against several new potential viruses. The EB66 cell ...

Companies will collaborate on antibody discovery against multiple targets. Vaccines company Sanofi Pasteur is paying Vivalis €3 million up front for exclusive access to the latter’s Humalex® platform ...

LONDON/PARIS (Reuters) - France's Vivalis and Austrian vaccine specialist Intercell are linking up in a rare cross-border deal that shows the need for Europe's fledgling biotech companies to grow in ...

Vivalis shareholders will own 55% of Valneva, with Intercell’s shares being converted at a 39% premium to the pre-deal share prices. An extra 8.6m shares will be issued to former Intercell ...

Valneva SE (Valneva) has announced the completion of the merger of equals between Vivalis and Intercell, creating a new European biotech company focusing on vaccines and antibodies, striving to become ...

The French vaccines manufacturing technology company Vivalis SA is acquiring Austrian vaccines discoverer and developer Intercell AG, of Vienna, in an all-share deal valued at €133 million (US$175 ...